📊 Peptide Side-Effect Explorer
Pick a symptom to see every published Phase 2/3 trial that reports it — sorted by frequency, with dose, population, and source citations.
1. Pick a symptom
Chips are sorted by the highest reported frequency across any trial — the ones at the top show up most often.
Trials reporting
7
Unique peptides
3
Mean frequency
9%
Range
6–11%
Trials reporting Fatigue
| Peptide | Trial | Dose & duration | Population | Frequency | Source |
|---|---|---|---|---|---|
| Semaglutide |
STEP-1
N=1,961 · 2021
|
2.4 mg SC weekly 68 weeks |
Obesity, no diabetes | NEJM 2021 | |
| Retatrutide |
TRIUMPH-1
N=2,339 · 2026
|
12 mg SC weekly 104 weeks |
Obesity, no diabetes | AJMC 2026 | |
| Semaglutide |
REDEFINE-1
N=3,417 · 2026
|
2.4 mg / 2.4 mg SC weekly 68 weeks |
Obesity | HCPLive 2026 | |
| Tirzepatide |
SURMOUNT-5
N=751 · 2026
|
Tirzepatide 15 mg vs Semaglutide 2.4 mg weekly 72 weeks |
Obesity, no diabetes | NEJM 2026 | |
| Semaglutide |
SURMOUNT-5
N=751 · 2026
|
Tirzepatide 15 mg vs Semaglutide 2.4 mg weekly 72 weeks |
Obesity, no diabetes | NEJM 2026 | |
| Tirzepatide |
SURMOUNT-1
N=2,539 · 2022
|
15 mg SC weekly 72 weeks |
Obesity, no diabetes | NEJM 2022 | |
| Semaglutide |
STEP-2
N=1,210 · 2021
|
2.4 mg SC weekly 68 weeks |
Obesity + T2D | Lancet 2021 |
About the data. Frequencies are drawn from published Phase 2/3 trial reports — primarily GLP-1 class (semaglutide, tirzepatide, retatrutide) where head-to-head placebo-controlled data is available. Absence of a symptom here means it was not a prespecified adverse event in that trial, not that it never occurs. Rare and long-tail events are under-represented.
v1 coverage:
9 distinct symptoms across 3 peptides and 7 landmark trials. Non-GLP-1 compounds (BPC-157, TB-500, GHK-Cu, etc.) are not yet included — their side-effect data comes mostly from case reports and preclinical work rather than randomised trials.
If you have a specific trial you'd like us to code, let us know.